Grifols, S.A. Reports the Successful Closing of the Private Placement of Additional 7.5% Senior Secured Notes Due 2030 (2024)

GRIFOLS, S.A.

Add to a list

To use this feature you must be a member

Log inSign up

Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 11:38:24 2024-06-07 am EDT			5-day change	1st Jan Change
9.348 ^EUR	-0.09%		+1.68%	-39.51%

Jun. 07	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	MT
Jun. 04	Grifols, S.A. Reports the Successful Closing of the Private Placement of Additional 7.5% Senior Secured Notes Due 2030	CI

June 04, 2024 at 10:52 am EDT

Grifols, S.A. reported the successful closing of the private placement of additional 7.5% senior secured notes due 2030 for an amount of EUR 300 million (the "Additional Notes"), which are additional to the EUR 1.0 billion notes originally issued on 30 April and also due in 2030 (the "Initial Notes") (OIR number 28379). The Additional Notes are additional to the Initial Notes, have the same economic terms as the Initial Notes and benefit from the same guarantees and security interest that currently guarantee and secure the Initial Notes. The proceeds from the Additional Notes have been received by the company on June 4, 2024 at a price of 98.5% of the principal amount of the Additional Notes and will be used to repay a portion of the Company?s revolving loans under its Credit and Guaranty Agreement entered into on November 15, 2019, as amended and restated from time to time.

Latest news about Grifols, S.A.

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Jun. 07	MT
Grifols, S.A. Reports the Successful Closing of the Private Placement of Additional 7.5% Senior Secured Notes Due 2030	Jun. 04	CI
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	Jun. 03	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	May. 29	MT
Solaria expects energy prices to rise this year	May. 28	RE
Solaria sees higher energy prices later this year, shares rise	May. 27	RE
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	May. 23	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	May. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	May. 17	MT
GRIFOLS : In line Q1 and on track deleveraging; worth a go	May. 15
Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Grifols swings to first-quarter profit, says guidance on track	May. 14	RE
Grifols' CFO Alfredo Arroyo Will Leave Company Next Year	May. 14	RE
GRIFOLS' CFO ALFREDO ARROYO WILL LEAVE COMPANY NEXT Y…	May. 14	RE
Grifols posts first-quarter profit of 21 million euros	May. 14	RE
GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO…	May. 14	RE
Transcript : Grifols, S.A., Q1 2024 Earnings Call, May 14, 2024	May. 14
Spain's Grifols swings to first-quarter profit of 21 mln euros	May. 14	RE
Grifols shares fall after new Gotham City Research report	May. 14	RE
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	May. 13	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	May. 08	MT
Sector Update: Health Care Stocks Advance in Monday Afternoon Trading	May. 06	MT
Grifols Shares Rise as Haier Deal Set to Close in June	May. 06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT

Chart Grifols, S.A.

Duration

Period

More charts

Company Profile

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:- products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries;- diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;- other (3.1%): primarily intermediate biological products and subcontracted manufacturing services.Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).

Sector

Pharmaceuticals

Income Statement Evolution

More financial data

Analysis / Opinion

GRIFOLS : In line Q1 and on track deleveraging; worth a go May 15, 2024 at 07:54 am EDT

Gotham City sets its sights on Grifols January 09, 2024 at 10:09 am EST

More Strategies

Ratings for Grifols, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.348EUR

Average target price

17.35EUR

Spread / Average Target

+85.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GRIFOLS, S.A.	-39.51%	6.19B
CSL LIMITED	+0.82%	93.19B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	39.62B
BIOGEN INC.	-12.88%	33.78B
UCB	+64.77%	26.82B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.35B
INCYTE CORPORATION	-5.78%	13.13B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	9.43B

Biopharmaceuticals

Stock Market
Equities
GRF Stock
News Grifols, S.A.
Grifols, S.A. Reports the Successful Closing of the Private Placement of Additional 7.5% Senior Secured Notes Due 2030

Like the pros, access all the transcripts and spot the best opportunities before anyone else. Unlock them now!

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '25530828');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });